Clarity Diagnostics

Executive Summary

Clarity Diagnostics is a US-based manufacturer of rapid diagnostic tests and point-of-care (POC) equipment headquartered in San Diego, founded in 2015. The company develops and commercializes tests across infectious diseases, urinalysis, pregnancy, glucose monitoring, cancer screening, and drugs of abuse, targeting Continuum of Care, Alternative Care, Acute Care, Laboratory, and Over-the-Counter (OTC) markets. As a private entity with no disclosed funding or revenue, Clarity Diagnostics operates in the competitive POC diagnostics space, leveraging a broad test menu to address multiple care settings. The growing demand for rapid, decentralized testing—driven by the shift toward value-based care and pandemic preparedness—positions the company for potential expansion. However, without public financials or product-specific milestones, the company's near-term trajectory relies on regulatory clearances and commercial partnerships. Key catalysts include FDA approvals for new assays, strategic distribution agreements, and platform expansions to penetrate new market segments. The company's ability to differentiate through quality, cost, and breadth will be critical in capturing share from established players like Abbott and QuidelOrtho.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for a rapid respiratory panel test70% success
• Q2 2026Strategic distribution partnership with a national laboratory or hospital network60% success
• Q4 2026Launch of a multi-analyte point-of-care platform combining infectious disease and metabolic tests50% success